UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022

MONTE ROSA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-40522**	**84-3766197**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

645 Summer Street, Suite 102
Boston, MA 02210
(Address of principal executive offices, including zip code)

(617) 949-2643
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	**GLUE**	**The Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Monte Rosa Therapeutics, Inc. (the "Company") will be conducting meetings with investors attending the 40th Annual J.P. Morgan Healthcare Conference (the "Conference"), which is taking place virtually beginning on January 10, 2022. As part of these meetings, the Company will deliver its revised corporate presentation, furnished to this report as Exhibit 99.1 and which is incorporated herein by reference (the "Materials"). The Company will also present a portion of the Materials at the Conference.

The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate presentation furnished by Monte Rosa Therapeutics, Inc. on January 10, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Monte Rosa Therapeutics, Inc.

Date: January 10, 2022

By: /s/ Markus Warmuth
Markus Warmuth
President and Chief Executive Officer

Exhibit 99.1

From Serendipity to Rational Design

Taking Molecular Glue Degraders to New Heights | January 2022

Monte Rosa Therapeutics

Forward-Looking Statements

These materials include express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in these materials include, but are not limited to, statements about our product development activities, including our expectations around the ongoing development of our QuEENTM platform and in silico tools, the advancement of our pipeline and the various products therein, including -the timing for filing our IND for our GSPT1 program and the advancement of additional programs, the expansion of our compound and degron libraries, our ability to identify additional molecular glue degraders, and our scientific predictions around clinical opportunities for our programs, including for GSPT1 program. By their nature, these statements are subject to numerous risks and uncertainties, including the impact that the current COVID-19 pandemic will have on our development activities and operations, as well as those risks and uncertainties set forth in our Quarterly Report on Form 10-Q for the third quarter ended September 30, 2021 filed with the US Securities and Exchange Commission, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, it has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.

Monte Rosa Therapeutics Highlights

Taking molecular glue degraders (MGDs) to new heights

Next-generation molecular glue-based targeted protein degradation platform developing breakthrough small molecule drugs that selectively degrade therapeutically-relevant proteins

Targeting the undruggable proteome via AI-based degron prediction & rational design of highly selective MGDs

IND for GSPT1 program expected in 2022 with clinical development planned in Myc-driven tumors

Five disclosed programs targeting high unmet medical needs in oncology and non-oncology indications

World-class leadership & SAB with deep drug discovery know-how and development expertise in precision medicine

World-Class Leadership

Deep expertise in molecular glue discovery, drug development and precision medicine

Markus Warmuth, M.D.
Chief Executive Officer

H3 Biomedicine
Novartis

Ajim Tamboli, CFA
Chief Financial Officer

Columbia Threadneedle Investments
Lehman Brothers

Owen Wallace, Ph.D.
Chief Scientific Officer

Fulcrum Therapeutics
Novartis

Sharon Townson, Ph.D.
Chief Technology Officer

Kymera
Warp Drive Bio

John Castle, Ph.D.
Chief Data Scientist

agenus
BioNTech

Filip Janku, M.D., Ph.D.
Chief Medical Officer

The University of Texas MD Anderson Cancer Center

Jullian Jones, Ph.D., J.D., MBA
Chief Business Officer

Lilly
Boehringer Ingelheim

Silvia Buonamici, Ph.D.
SVP, Drug Discovery Biology

H3 Biomedicine
Novartis

Phil Nickson, Ph.D., J.D.
SVP, Head, Legal Operations

Momenta
Fish & Richardson

Jennifer Champoux,
Vice President, Operations

H3 Biomedicine
Novartis

Strong Cash Position and Investor Support

Over $455M raised since 2020 with top tier investors provides runway into late 2024

VERSANT ventures · NEA · Fidelity INVESTMENTS · T.RowePrice

BlackRock · AVORO CAPITAL ADVISORS · HBM Healthcare Investments · Cormorant Asset Management · CASDIN CAPITAL LIFE SCIENCE INVESTMENTS

RTW Investments · G/ · AISLING CAPITAL · AMZAK CAPITAL MANAGEMENT · SIXTY DEGREE CAPITAL

Aggregate IPO gross proceeds were approximately $255.6 million before deducting underwriting discounts and commissions and other offering expenses and include an additional $33.3 million in gross proceeds the company received as part of its IPO from the full exercise of the underwriters' option to purchase up to an additional 1,755,000 shares of common stock at the public offering price of $19.00 per share.

Expanding Target Space through Molecular Glue Degraders (MGDs)



Drugging the Druggable

Redrugging the Druggable

Drugging the Undruggable

3-10% of Proteome

Uncharted Chemical and Target Space

The Next Generation of Precision Medicine-based Small Molecule Drugs

Selectively editing the human proteome with rationally designed MGDs

	Traditional small molecule inhibitors	Therapeutic Antibodies	MGDs	RNAi, RNA Editing	CRISPR/Gene Therapy
Ability to access undruggable space	X	✓	✓	✓	✓
Cellular permeability	✓	X	✓	✓	✓
Oral bioavailability	✓	X	✓	X	X
Systemic distribution	✓	✓	✓	X	X
CNS Penetration	✓	X	✓	X	X
Manufacturing scalability	✓	✓	✓	X	X

Our Rational Approach to Unleash the Full Potential of MGDs



Monte Rosa Therapeutics

QuEEN™ Discovery Platform

Quantitative and Engineered Elimination of Neosubstrates

QuEEN™ Discovery Platform: A Target-Centric Approach to MGDs

Degron encyclopedia

Degron discovery using proprietary AI-powered algorithm



Sequence

Topology

Surface

1000s of proteins across multiple degrons

Proprietary MGD library

Rationally designed, diverse and growing library engaging a variety of degrons



Cereblon binding (pIC_{50})

5 7

Molecular weight (Da)

190 300

Glueomics™ toolbox

Specialized suite of *in vitro* and *in silico* assays to discover, optimize and advance MGDs as clinical candidates



Accessing a large pool of undruggable targets with a diverse MGD library

A Rich, Differentiated Target Space Across Protein Domains and Diseases

Degron Encyclopedia
>3000 proteins containing a predicted loop degron

Degron-containing domains



Broad disease landscape



Predicted degrons



Diverse protein domains and classes

>85% degrons have unique sequence

>75% undruggable

Many highly credentialed targets

Increasing Novelty and Structural Diversity to Match the Target Space

Increasing MGD scaffold diversity



MGD library is derived from **> 400 unique low molecular weight scaffolds** with **favorable CRBN binding** affinities

Library design and expansion

- Design focused on optimal drug-like properties
- High structural diversity and novelty
- Current library size 20K MGDs

MGDs Reprogram the Cereblon Surface

Remodeled MGD-CRBN surface enables selective engagement of neosubstrates

Multiple points of contact for dialing in selectivity and potency



Effective ternary complex generation involves

- MGD-cereblon interactions
- MGD-neosubstrate interactions
- CRBN-neosubstrate interactions

MGDs are rationally designed to exploit key contacts to selectively engage different neosubstrates



MGDs reshape the cereblon surface through different exit vector geometries

Neosubstrates are engaged selectively through unique interactions with both MGD and cereblon

Glueomics™ Toolbox Accelerates Identification of MGDs

Multiple assays enable rapid identification and validation of MGDs for novel targets

in vitro screens



Biochemical



Cellular

Chemoproteomics - proximity



Turbo-ID

Proteome-wide expression



TMT Proteomics to evaluate:

- Proteome-wide changes in protein levels
- MGD selectivity

Rhapsody, QuEEN's *in silico* Engine

A suite of proprietary AI-powered algorithms to design, discover and develop MGDs

in silico library generation

Creation and E3 ligase docking of novel MGDs, expanding our library to engage more targets



in silico ternary complex models

Ternary complex models enabling MRT scientists to engineer and optimize selective MGDs



in silico MGD screening

Computational screening identifying and prioritizing hits inducing binding and selective degradation



Taking MGD discovery in silico to accelerate discovery

Leveraging a Leading Drug Discovery Platform

Purpose-built to discover and develop a wide landscape of therapeutically-relevant MGDs

Monte Rosa's High-Value Proprietary Pipeline

Targets

Undruggable and inadequately drugged degron-containing proteins

High level of target validation, preclinically and clinically

Clinical Path

Programs with biomarker-based patient selection strategy and clear path to the clinic

Opportunity for rapid clinical PoC for MOA and efficacy

Patient Benefit

Address high unmet needs

Potential to address a wide range of therapeutically-relevant proteins in oncology and beyond

Create synergies within therapeutic areas

Monte Rosa Pipeline

Rapidly advancing wholly owned MGD programs targeting undruggable proteins

Monte Rosa Therapeutics

GSPT1 Program

Targeting Myc-driven Tumors and Their Addiction to Protein Translation

GSPT1 is a key regulator and vulnerability of Myc-induced translational addiction

Myc hijacks the cellular protein translation machinery creating a vulnerability to GSPT1



To sustain growth, Myc-driven tumors are **addicted to protein translation**

- Myc regulates the expression of key genes related to protein translation, including the master regulator 4EBP1 and eIF4E

This addiction to protein translation creates a **dependency** to the translation termination factor GSPT1 a degron-containing protein

GSPT1 MGDs exploit this **vulnerability** by:

- Disrupting protein translation output
- Reducing Myc-oncogenic signaling

MRT-2359 is a Potent and Selective GSPT1-directed MGD

MRT-2359 is a potent inducer of GSPT1-cereblon proximity

Ternary complex model



in vitro data	
CRBN binding, K_i	113 nM
Ternary complex, EC_{50}	< 7 nM
Degradation, DC_{50}	80 nM

MRT-2359 is a selective GSPT1-directed MGD



6hr post treatment in MM1S and Kelly (SALL4)



1hr post treatment

Myc-Driven NSCLC lines are Highly Sensitive to MRT-2359

Myc-driven NSCLC cell lines are sensitive to MRT-2359



MRT-2359 induces GSPT1 degradation in all cell models, but selective killing in high N-Myc lines only



GSPT1 western blot at 6 hr (N-Myc high) and 24 hr (low). 72 hr viability assay (CTG)

MRT-2359 Affects N-Myc Pathway only in Myc-driven Cells

GSPT1-directed MGD degradation affects translation, a critical vulnerability of Myc-driven cells



Myc-driven (NCI-H1155)



Non-Myc-driven (NCI-H2023)



MRT-2359 Induces Tumor Regressions in N-Myc-driven Xenograft Models

Oral dosing of MRT-2359 shows anti-tumor activity and regressions in NCI-1155

Similar observations in other high N-Myc expression models (ABC-1, NCI-H1770)



Dose- and time-dependent degradation of GSPT1 is associated with N-Myc downregulation



MRT-2359 Anti-tumor Activity in L- and N-Myc-positive NSCLC PDXs



Tumor progression to ≥800 mm^3

Targeting Myc-positive Tumors with MRT-2359

Potential indications and patient stratification hypotheses



Patient diagnosed incidence #s, major markets (US, EU and JP): Decision Resources Group (DRG)
Patient stratification %s: Schaub - Cell Systems 2018; Massó-Vallés – Exp. Op. therapeutic targets 2020; Sesques and Johnson - Blood 2016

Early Phase Clinical Development

Dose escalation

BOIN design

Lung cancer (NSCLC, SCLC), solid tumors with L-/N-Myc amplification and diffuse large B-cell lymphomas



MTD or RDE

Expansion cohorts

NSCLC – Enriched for high L-/N-Myc expression

SCLC – Enriched for high L-/N-Myc expression

Solid tumors – L-/N-Myc amplification

Targeting Myc-addicted Tumors with MRT-2359

IND-enabling activities have been initiated

Rationally designed **potent and selective** GSPT1-directed MGD

Favorable **drug-like properties** and ADMET profile

Orally bioavailable development candidate

Robust **antitumor activity** *in vivo* in **multiple tumor models**

IND-enabling activities ongoing

Patient stratification hypothesis developed and being validated

IND filing expected in mid-2022

Monte Rosa Therapeutics

NEK7 Program

NEK7 (NIMA-Related Kinase 7) as a Target for Inflammatory Disease

NEK7 is an essential regulator of the inflammasome



Therapeutic hypothesis: Diseases with over-activated or mutated NLRP3 inflammasome

- NEK7 licenses NLRP3 assembly in a kinase independent manner
- NEK7-deficient macrophages are severely impaired in IL-1β and IL-18 secretion

Clinical opportunity: First-in-class NEK7 degraders for

- Over-activated NLRP3 inflammasome: metabolic pathologies, cardiovascular diseases, inflammatory issues and neurologic disorders
- NLRP3 activating mutations: Cryopyrin-associated periodic syndromes (CAPS)

Rationally Designed NEK7-Directed MGDs are Selective

Rhapsody model enables rapid chemistry optimization



in vitro data	
CRBN binding, K_i	48 nM
Ternary complex, EC_{50}	20 nM
Degradation, DC_{50}	10 nM

Rationally designed MGDs promote selective CRBN proximity



Turbo-ID – 6hr post treatment

NEK7-directed MGD promotes selective degradation of NEK7



TMT-Proteomics – 24hr post treatment

NEK7-directed MGDs Modulate NLRP3 Pathway in Human Macrophages

MRT-3483 promotes NEK7 degradation and pathway engagement in hMDMs





Western blot – 24 hr

Treatment (6hr) of primed hMDMs

NEK7-directed MGD compared to NLRP3 inhibitor

IL-18



IL-1β



Treatment (20 hr) of primed hMDMs

CASP1 and LDH showed similar profile

Overactivation of the NLRP3 Inflammasome in Diseases

NLRP3 activating mutations



NLRP3 mutations found in CAPS (Cryopyrin-associated periodic syndromes – MWS*, FCAS**, CINCA/NOMID# Syndrome) might stabilize the active form of NLRP3

Over-activated NLRP3 inflammasome



*Muckle-Wells Syndrome
**familial cold autoinflammatory syndrome, #Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease

Monte Rosa Therapeutics

CDK2 Program

CDK2 as a Target for Selected Solid Tumors

CDK2 is one of the key regulators of the cell cycle



Therapeutic hypothesis: Tumors with CDK2 pathway activation by:

- CyclinE1/E2 amplification or loss of AMBRA1
- Loss of RB

Clinical Opportunity: CDK2 driven cancers: ER positive breast cancer (444K patients), ovarian cancer (63K patients), and endometrial cancer (118K patients), as well as breast cancer post treatment with CDK4/6 inhibitors

Rationally Designed CDK2-Directed MGDs are Selective

Rhapsody model enables rapid chemistry optimization



in vitro data	
CRBN binding, K_i	163 nM
Ternary complex, EC_{50}	9 nM

Rationally designed MGD promotes selective CRBN proximity



Turbo-ID – 6hr post treatment

CDK2-directed MGD promotes selective degradation



TMT-Proteomics – 24hr post treatment

Program advanced to lead optimization in Q4 2021

Monte Rosa Therapeutics

VAV1 and BCL11a Programs

VAV1 as a Target for Autoimmune Disease

VAV1 plays a key role in T-cell and B-cell development and activation



Therapeutic hypothesis: Diseases with VAV1 activating mutations or autoimmune disorders

- VAV1 activation mutations identified in leukemia, lymphoma and lung cancer
- VAV1 KO mice improved multiple autoimmune models

Clinical Opportunity: First-in-class VAV1 degraders for

- T-cell and B-cell lymphomas: DLBCL (66K patients) and Burkitt lymphoma
- Autoimmune disorders including MS (1.2M patients), myasthenia gravis (36K – 60K patients in US), and acute graft-versus-host disease (10K patients)

Patient diagnosed prevalence and incidence #s, major markets (US, EU and JP): DRG; myasthenia.org

BCL11A as a Target for Hemoglobinopathies (SCD and β-Thalassemia)

BCL11A is the zinc finger transcription repressor of the fetal globin genes



Therapeutic hypothesis: Reactivate expression of fetal hemoglobin (HbF) to compensate for mutated adult globin

Clinical Opportunity: First-in-class BCL11A degraders for

- Sickle cell disease (SCD)
  - 155,000 patients (US and EU)
  - >6M patients (ROW)
- β-thalassemia
  - 17,000 patients (US and EU)

Patient diagnosed prevalence #s: DRG; www.notaloneinsicklecell.com

Monte Rosa Therapeutics

Summary

Monte Rosa Therapeutics

From serendipity to rational design of MGDs

Molecular glue-based targeted protein degradation platform developing breakthrough small molecule therapeutics that selectively degrade disease-causing proteins

Proprietary, **target-centric** drug discovery platform enabling **rational design**, and anticipated rapid development, of molecular glue-based degraders targeting the **undruggable proteome in oncology** and **non-oncology disease**

Initial platform focus on **cereblon-mediated protein degradation** with **hundreds of potential targets** to address

Extensive and compelling pre-clinical *in vivo* data for GSPT1 program, demonstrating **potent anti-tumor activity** in Myc-driven tumor models

IND filing for GSPT1 program expected in mid-2022; additional programs at various stages of discovery

Potential to reprogram other E3 ligases to access more of the undruggable proteome through other degrons


Thank You
Monte Rosa
Therapeutics